Successful treatment of tafro syndrome with tocilizumab, prednisone, and cyclophosphamide

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

TAFRO syndrome is a rare systemic inflammatory disease characterized by thrombocytopenia, pleural effusion, fever, renal dysfunction, reticulin fibrosis of the bone marrow, and organomegaly. The clinical course varies significantly among patients. However, the prognosis is usually dismal in patients with severe TAFRO syndrome, and no optimal treatment has yet been established. We herein describe the first case of TAFRO syndrome, which was successfully treated with combination therapy consisting of tocilizumab, prednisone, and cyclophosphamide.

Original languageEnglish
Pages (from-to)2205-2211
Number of pages7
JournalInternal Medicine
Volume56
Issue number16
DOIs
Publication statusPublished - 2017

Fingerprint

Prednisone
Cyclophosphamide
Reticulin
Primary Myelofibrosis
Pleural Effusion
Thrombocytopenia
Fever
Therapeutics
Kidney
tocilizumab

Keywords

  • Cyclophosphamide
  • TAFRO syndrome
  • Tocilizumab

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Successful treatment of tafro syndrome with tocilizumab, prednisone, and cyclophosphamide. / Kikuchi, Taku; Shimizu, Takayuki; Toyama, Takaaki; Abe, Ryohei; Okamoto, Shinichiro.

In: Internal Medicine, Vol. 56, No. 16, 2017, p. 2205-2211.

Research output: Contribution to journalArticle

@article{0ef401d30fe0482f848e5e1c10b298b8,
title = "Successful treatment of tafro syndrome with tocilizumab, prednisone, and cyclophosphamide",
abstract = "TAFRO syndrome is a rare systemic inflammatory disease characterized by thrombocytopenia, pleural effusion, fever, renal dysfunction, reticulin fibrosis of the bone marrow, and organomegaly. The clinical course varies significantly among patients. However, the prognosis is usually dismal in patients with severe TAFRO syndrome, and no optimal treatment has yet been established. We herein describe the first case of TAFRO syndrome, which was successfully treated with combination therapy consisting of tocilizumab, prednisone, and cyclophosphamide.",
keywords = "Cyclophosphamide, TAFRO syndrome, Tocilizumab",
author = "Taku Kikuchi and Takayuki Shimizu and Takaaki Toyama and Ryohei Abe and Shinichiro Okamoto",
year = "2017",
doi = "10.2169/internalmedicine.8522-16",
language = "English",
volume = "56",
pages = "2205--2211",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "16",

}

TY - JOUR

T1 - Successful treatment of tafro syndrome with tocilizumab, prednisone, and cyclophosphamide

AU - Kikuchi, Taku

AU - Shimizu, Takayuki

AU - Toyama, Takaaki

AU - Abe, Ryohei

AU - Okamoto, Shinichiro

PY - 2017

Y1 - 2017

N2 - TAFRO syndrome is a rare systemic inflammatory disease characterized by thrombocytopenia, pleural effusion, fever, renal dysfunction, reticulin fibrosis of the bone marrow, and organomegaly. The clinical course varies significantly among patients. However, the prognosis is usually dismal in patients with severe TAFRO syndrome, and no optimal treatment has yet been established. We herein describe the first case of TAFRO syndrome, which was successfully treated with combination therapy consisting of tocilizumab, prednisone, and cyclophosphamide.

AB - TAFRO syndrome is a rare systemic inflammatory disease characterized by thrombocytopenia, pleural effusion, fever, renal dysfunction, reticulin fibrosis of the bone marrow, and organomegaly. The clinical course varies significantly among patients. However, the prognosis is usually dismal in patients with severe TAFRO syndrome, and no optimal treatment has yet been established. We herein describe the first case of TAFRO syndrome, which was successfully treated with combination therapy consisting of tocilizumab, prednisone, and cyclophosphamide.

KW - Cyclophosphamide

KW - TAFRO syndrome

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=85027560802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027560802&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.8522-16

DO - 10.2169/internalmedicine.8522-16

M3 - Article

C2 - 28781319

AN - SCOPUS:85027560802

VL - 56

SP - 2205

EP - 2211

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 16

ER -